PhaseBio Pharmaceuticals, Inc. (PHAS) is a clinical-stage biopharmaceutical entity primarily dedicated to discovering, developing, and bringing to market innovative therapies for cardiovascular conditions. Its flagship product in development, bentracimab (PB2452), serves as a reversal agent specifically designed to counteract the effects of the antiplatelet medication ticagrelor. This drug is presently in Phase III clinical trials, targeting patients who are experiencing severe, uncontrolled, or life-threatening bleeding events, or those requiring immediate surgical or invasive interventions. The company's pipeline also features PB1046, a vasoactive intestinal peptide analogue under investigation for pulmonary arterial hypertension, and PB6440, being developed for the management of resistant hypertension. PhaseBio has a strategic co-development alliance with SFJ Pharmaceuticals X, Ltd. for PB2452. Established in 2002 and situated in Malvern, Pennsylvania, PhaseBio Pharmaceuticals, Inc. initiated voluntary reorganization proceedings under Chapter 11 bankruptcy on October 23, 2022, in the U.S. Bankruptcy Court for the District of Delaware.